Emas Articles & Analysis: Older
15 articles found
Creative Bioarray's reporting complies with FDA and EMA regulatory requirements for pharmaceuticals for human use (ICH Guidelines Q5B and Q5D, CTD Quality ...
Medical advancement relies on clinical trials, which are essential for the development of safe and effective innovative treatments. However, the success and general applicability of these treatments heavily depend on the diversity of the participants involved¹?³. This blog explores the importance of achieving data diversity in clinical trials to enhance clinical trial results and ...
Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have strict guidelines requiring biopharmaceutical companies to detect and control HCP levels.Detection Methods1. ...
This may include lab-scale spike experiments to demonstrate the removal of impurities derived from cell substrates, such as nucleic acids and host cell proteins. The European Medicines Agency (EMA) guidelines CPMP / BWP / 382/97 point out that for HCP, regardless of the product and production system, the residual HCP must be tested regularly. ...
Moreover, regulatory authorities like the FDA and EMA require in vitro DMPK and ADMET data, making these studies indispensable for the successful application and approval of drugs. ...
Caplacizumab was initially approved for marketing by the EMA in September 2018, and was subsequently approved for marketing by the US FDA, Japan PMDA and other drug regulatory agencies.Ozoralizumab contains three VHH domains, two of which target tumor necrosis factor α (TNF-α) and bind to the two subunits of TNFα. ...
Moreover, regulatory authorities like the FDA and EMA require in vitro DMPK and ADMET data, making these studies indispensable for the successful application and approval of drugs. ...
Creative Bioarray's reporting complies with FDA and EMA regulatory requirements for pharmaceuticals for human use (ICH Guidelines Q5B and Q5D, CTD Quality ...
Currently, four SGLT2is (empagliflozin, dapagliflozin, canagliflozin, and ertugliflozin) are licensed by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). Empagliflozin in HFpEF (EMPEROR-Preserved) The EMPEROR-Preserved trial, released in 2021, is the first randomized controlled trial testing the efficacy and safety of SGLT2is (empagliflozin) in ...
CDISC has been recognised by the International Organization for Standardisation (ISO) and several of their research standards are now required by healthcare regulations in the US (FDA), Japan (PMDA) and the European Medicines Agency (EMA) for clinical trial applications. In summary, implementing CDISC standards can greatly promote efficiency, improve data quality and sharing, ...
ByLifebit
Introduction to the CT Portal and Database: The European Medicines Agency (EMA) will release and host the CT Portal and Database which aims to support the new CTR. ...
ByDDi LLC
The digital pathology software company PathPresenter (Montville, New Jersey) and the precision oncology platform firm 4D Path have entered into a partnership that could improve the diagnostic accuracy of breast tumor profiling. PathPresenter has developed a digital workflow tool for clinicians, pathologists and pharma companies to aggregate medical data. ...
Recent Regulation The FDA has issued recent regulation on stem cell products in the following ways: Published their perspective on stem cell therapy in the New England Journal of Medicine Increased regulation enforcement for stem cell clinics Released new guidance, Regulatory Consideration for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous ...
For example the European Medicines Agency (EMA) requires euglycaemic clamp technique data in the form of time action profiles in order to register a new insulin type for the treatment of diabetes. ...
The principle of Environmental management - “polluter-pays principle” in Tanzania as highlighted in her Environment Management Act (EMA) of 2004 adopted from Act No. 3 of 2003 means a mechanism whereby the cost of cleaning up any element of the environment damaged is to be paid or borne by the person convicted of pollution.Asking on"How much How much must the polluter ...